SCP
VIVO

Seizert Capital Partners’s Meridian Bioscience Inc VIVO Stock Holding History

Seizert Capital Partners’s Portfolio VIVO Stock Details VIVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-20,988
Closed -$638K – 207
2022
Q2 		$638K Hold
20,988
– – 0.03% 156
2022
Q1 		$545K Hold
20,988
– – 0.03% 169
2021
Q4 		$428K Buy
+20,988
New +$402K 0.02% 178
2020
Q1 		– Sell
-67,681
Closed -$661K – 239
2019
Q4 		$661K Buy
67,681
+26,651
+65% +$250K 0.03% 143
2019
Q3 		$389K Buy
+41,030
New +$432K 0.02% 165

Other funds holding VIVO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Impactive Capital New York City, New York $1.38B AUM 1.92% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Seizert Capital Partners's VIVO Position: Q3 2022 in Review

Seizert Capital Partners sold out of Meridian Bioscience Inc (VIVO) in Q3 2022, closing a stake of 20,988 shares — an estimated $638K sold.

Seizert Capital Partners first reported a position in VIVO in Q3 2019 and held it in 5 quarters. The position peaked at $661K in Q4 2019. 203 funds tracked by Wall St. Rank hold VIVO as of Q3 2022.

  • Seizert Capital Partners reported no remaining Meridian Bioscience Inc position as of Q3 2022 after selling out during the quarter.
  • Seizert Capital Partners sold 20,988 Meridian Bioscience Inc shares in Q3 2022, an estimated $638K.
  • Seizert Capital Partners first reported a position in Meridian Bioscience Inc in Q3 2019 and held it in 5 quarters.
  • Seizert Capital Partners's Meridian Bioscience Inc position peaked at $661K in Q4 2019.
  • 203 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q3 2022.

Based on Seizert Capital Partners's 13F filing for Q3 2022, filed 2 Nov 2022.